D.C. Circuit Rescheduling Challenge: What Investors Need to Know

Standing Requirements Create First Procedural Gate

Petitioners challenging the DEA's Notice of Proposed Rulemaking under 21 U.S.C. § 811(a) must demonstrate concrete injury to establish Article III standing, a requirement that several filings may not satisfy. The Administrative Procedure Act permits judicial review only when a party shows it suffered or will imminently suffer particularized harm. Generic claims that rescheduling harms public health or conflicts with state regulatory schemes have historically failed this test in D.C. Circuit challenges to agency rules.

The DEA published its NPRM in May 2024, triggering a 60-day comment period that closed in July 2024. Multiple petitions for review were filed in the D.C. Circuit between August 2024 and January 2025, consolidated under case number 24-1328. The court hasn't yet ruled on threshold jurisdictional questions.

Administrative law attorneys note that the Controlled Substances Act grants the Attorney General—delegated to the DEA Administrator—authority to reschedule substances based on HHS recommendations. The statute doesn't create a private right of action, meaning challengers must rely on APA Section 706 arbitrary-and-capricious review. That standard requires deference to agency expertise under Chevron unless the rule is unsupported by substantial evidence in the administrative record.

Timeline for Final Rule Remains Uncertain

The DEA hasn't announced a target date for issuing a final rule, and the agency faces no statutory deadline to complete rescheduling once an NPRM is published. Historical rescheduling actions have taken between 18 months and five years from initial petition to final rule. The current proceeding began with HHS's August 2023 recommendation to reschedule cannabis to Schedule III. That means the process is now approaching its third year with no final determination.

If the D.C. Circuit grants a stay of the rulemaking—an outcome legal observers consider unlikely absent a showing of irreparable harm—the DEA would be enjoined from finalizing the rule until the court resolves the merits. No motion for preliminary injunction has been granted as of June 13, 2026. The court's briefing schedule, if one's been set, hasn't been publicly docketed.

Investor analysts tracking MSO equity valuations have cited the rescheduling timeline as a key variable in 2026-2027 EBITDA models, particularly for operators with significant 280E tax burdens. A final Schedule III rule would permit cannabis businesses to deduct ordinary business expenses under 26 U.S.C. § 280E, which currently disallows deductions for trafficking in Schedule I or II controlled substances. The tax benefit? Estimated at $1.2 billion to $1.8 billion annually across the U.S. licensed market, according to cannabis financial advisories.

Substantive Arguments Challenge Agency Discretion

Petitioners argue the DEA ignored evidence that cannabis has high abuse potential and lacks accepted medical use, the statutory criteria for Schedule I classification under 21 U.S.C. § 812(b)(1). Those arguments face an uphill battle. The APA's arbitrary-and-capricious standard doesn't permit courts to substitute their judgment for the agency's; challengers must show the DEA acted outside its statutory authority or failed to consider relevant factors in the administrative record.

HHS's scheduling recommendation, transmitted to the DEA in August 2023, concluded that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. That recommendation binds the DEA on scientific and medical matters under the Controlled Substances Act's bifurcated review structure. The DEA retains authority only to evaluate whether rescheduling serves the public interest and complies with international treaty obligations under the 1961 Single Convention on Narcotic Drugs.

Some petitioners have argued that the Single Convention prohibits Schedule III placement because cannabis is listed in Schedule I and Schedule IV of the treaty. The DEA addressed this argument in the NPRM, concluding that domestic rescheduling doesn't violate treaty obligations because the U.S. may implement stricter controls at the state level. Federal courts haven't tested that interpretation.

What Operators and Investors Should Watch

The next procedural signal will be the D.C. Circuit's ruling on motions to dismiss for lack of standing or a briefing schedule order, expected no earlier than August 2026. If the court dismisses petitions for lack of standing, the DEA would face no judicial obstacle to finalizing the rule. If the court reaches the merits, oral argument would likely occur in late 2026 or early 2027, with a decision following six to nine months later.

For context on the broader legal and regulatory landscape surrounding this challenge, see the CannIntel topic hub on the DEA rescheduling legal challenge. Operators should model both scenarios: a final rule effective in Q1 2027 and a prolonged legal challenge extending the timeline into 2028. The tax benefit is real. But the procedural path is longer and narrower than most industry coverage suggests.